U.S. Markets closed
  • S&P 500

    4,221.86
    -1.84 (-0.04%)
     
  • Dow 30

    33,823.45
    -210.22 (-0.62%)
     
  • Nasdaq

    14,161.35
    +121.67 (+0.87%)
     
  • Russell 2000

    2,287.46
    -27.23 (-1.18%)
     
  • Crude Oil

    71.06
    -1.09 (-1.51%)
     
  • Gold

    1,774.30
    -87.10 (-4.68%)
     
  • Silver

    25.95
    -1.86 (-6.69%)
     
  • EUR/USD

    1.1913
    -0.0087 (-0.7267%)
     
  • 10-Yr Bond

    1.5110
    -0.0580 (-3.70%)
     
  • Vix

    17.75
    -0.40 (-2.20%)
     
  • GBP/USD

    1.3923
    -0.0064 (-0.4553%)
     
  • USD/JPY

    110.2500
    -0.3630 (-0.3282%)
     
  • BTC-USD

    37,701.58
    -892.80 (-2.31%)
     
  • CMC Crypto 200

    937.28
    -32.59 (-3.36%)
     
  • FTSE 100

    7,153.43
    -31.52 (-0.44%)
     
  • Nikkei 225

    29,018.33
    -272.68 (-0.93%)
     

Companies Like ImpediMed (ASX:IPD) Are In A Position To Invest In Growth

  • Oops!
    Something went wrong.
    Please try again later.
·4 min read
  • Oops!
    Something went wrong.
    Please try again later.

We can readily understand why investors are attracted to unprofitable companies. By way of example, ImpediMed (ASX:IPD) has seen its share price rise 243% over the last year, delighting many shareholders. But while the successes are well known, investors should not ignore the very many unprofitable companies that simply burn through all their cash and collapse.

Given its strong share price performance, we think it's worthwhile for ImpediMed shareholders to consider whether its cash burn is concerning. In this report, we will consider the company's annual negative free cash flow, henceforth referring to it as the 'cash burn'. We'll start by comparing its cash burn with its cash reserves in order to calculate its cash runway.

Check out our latest analysis for ImpediMed

When Might ImpediMed Run Out Of Money?

A company's cash runway is the amount of time it would take to burn through its cash reserves at its current cash burn rate. As at December 2020, ImpediMed had cash of AU$19m and no debt. In the last year, its cash burn was AU$18m. So it had a cash runway of approximately 13 months from December 2020. While that cash runway isn't too concerning, sensible holders would be peering into the distance, and considering what happens if the company runs out of cash. You can see how its cash balance has changed over time in the image below.

debt-equity-history-analysis
debt-equity-history-analysis

How Well Is ImpediMed Growing?

On balance, we think it's mildly positive that ImpediMed trimmed its cash burn by 19% over the last twelve months. And considering that its operating revenue gained 25% during that period, that's great to see. On balance, we'd say the company is improving over time. While the past is always worth studying, it is the future that matters most of all. So you might want to take a peek at how much the company is expected to grow in the next few years.

Can ImpediMed Raise More Cash Easily?

While ImpediMed seems to be in a fairly good position, it's still worth considering how easily it could raise more cash, even just to fuel faster growth. Companies can raise capital through either debt or equity. One of the main advantages held by publicly listed companies is that they can sell shares to investors to raise cash and fund growth. By looking at a company's cash burn relative to its market capitalisation, we gain insight on how much shareholders would be diluted if the company needed to raise enough cash to cover another year's cash burn.

ImpediMed has a market capitalisation of AU$179m and burnt through AU$18m last year, which is 10% of the company's market value. As a result, we'd venture that the company could raise more cash for growth without much trouble, albeit at the cost of some dilution.

How Risky Is ImpediMed's Cash Burn Situation?

The good news is that in our view ImpediMed's cash burn situation gives shareholders real reason for optimism. One the one hand we have its solid cash burn relative to its market cap, while on the other it can also boast very strong revenue growth. While we're the kind of investors who are always a bit concerned about the risks involved with cash burning companies, the metrics we have discussed in this article leave us relatively comfortable about ImpediMed's situation. Taking a deeper dive, we've spotted 3 warning signs for ImpediMed you should be aware of, and 1 of them is concerning.

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies, and this list of stocks growth stocks (according to analyst forecasts)

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.